Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
Authors' conclusion
180-day GLP-1 discontinuation was prevalent. ADR and cost concerns were primary reasons for discontinuation and health disparities among patients who discontinued were identified. These real-world findings offer patients, providers, and policymakers evidence of potential barriers to GLP-1 persistence.
Study context
- Population
- Adults with an initial GLP-1 (semaglutide or liraglutide) dispensed between January 1, 2018 and June 30, 2023
- Participants
- 1,374 adults
- Outcome
- GLP-1 discontinuation rate and, among those who discontinued, documented reasons for discontinuation
- Follow-up
- 180 days
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
GLP-1 discontinuation
Discontinued GLP-1 therapy
436
31.7%
Reason: Adverse drug reaction (ADR)
26.8%
Reason: GLP-1 cost concern
14.4%
Reason: non-adherence
11.2%
Observational data: associations, not effects.
Secondary outcomes
| Outcome | aOR (95% CI) | |
|---|---|---|
| Patient characteristics associated with GLP-1 discontinuationAsian/Native American/Pacific Islander racesvs Whites | 2.51 (1.07–5.91) | |
| Patient characteristics associated with GLP-1 discontinuationOverweight/obesity indicationvs Diabetes + overweight/obesity | 2.46 (1.17–5.17) | |
| 0.20.5125Adjusted odds ratio (log scale) |
Original publication
Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist. Diabetes Obes Metab. Published 19 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →